Paper Details

  1. Home
  2. Paper Details

Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.

Author: HyslopWilliam B, LeeYueh Z, NapravnikSonia, WilkinAimee, WohlDavid A, YoungLaura

Clinical StudyResearch involving human participants to assess the safety, efficacy, and effects of an intervention/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the effects of raltegravir (RAL) plus tenofovir/emtricitabine (TDF/FTC) on metabolic parameters in African-American (AA) patients with HIV infection.
Paper Details　
Original Abstract of the Article :
Raltegravir (RAL) plus tenofovir/emtricitabine (TDF/FTC) is a recommended initial antiretroviral regimen. A substantial proportion of persons diagnosed with HIV infection and starting antiretrovirals in the U.S. are African-American (AA); however, the effects of this regimen on metabolic parameters ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26249671

データ提供：米国国立医学図書館（NLM）

Raltegravir and Body Shape: A Journey Through Metabolic Changes

This study investigates the effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy. It's like a camel caravan exploring the metabolic landscape of HIV treatment, seeking to understand the impact of different drug combinations. The researchers found that raltegravir plus tenofovir/emtricitabine, while an effective antiretroviral regimen, had a noticeable effect on metabolic parameters, including an increase in body fat.

The Desert of Metabolic Changes: Navigating HIV Treatment

The study reveals that HIV treatment regimens can have significant effects on metabolic parameters, underscoring the need for close monitoring and management of metabolic changes during HIV therapy.

Navigating the Desert of HIV Treatment: A Focus on Metabolic Health

This study highlights the importance of considering the metabolic impact of antiretroviral medications, particularly for African-American patients. It emphasizes the need for personalized care plans that address both viral suppression and metabolic health.

Dr. Camel's Conclusion

This study underscores the complexities of HIV treatment and the need for a comprehensive approach that considers both viral suppression and metabolic health. It's a reminder that the desert of HIV treatment is not just about fighting the virus, but also about navigating the potential metabolic challenges that come with treatment.
Date :
  1. Date Completed 2016-02-04
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

26249671

DOI: Digital Object Identifier

NIHMS958463

Related Literature

Article Analysis
・Effects of raltegravir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.